Update on the treatment and prevention of ocular thelaziosis (Thelazia callipaeda) in naturally infected dogs from Spain. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Marino, Valentina; Gálvez, Rosa; Mascuñán, Carmen; Domínguez, Inés; Sarquis, Juliana; Montoya, Ana; Barrera, Juan Pedro; Zenker, Clara; Checa, Rocío; Hernández, Mauro; Miró, Guadalupe
• Is Part Of: International journal for parasitology. Volume 51:Issue 1(2021)
• Page Start: 73
• Page End: 81
• Publication Date: 2021-01
• Subjects: Dogs -- Ivermectin -- Milbemycin oxime -- Moxidectin -- Prevention -- Thelazia callipaeda -- Treatment; Parasitology -- Periodicals; Parasitology -- Periodicals; Parasitologie -- Périodiques; Parasitology; Periodicals; Electronic journals; 571.999
• DOI: 10.1016/j.ijpara.2020.08.007
• Languages: English
• ISSNs: 0020-7519

Abstract

Graphical abstract: Highlights: Appropriate management of Thelazia callipaeda is being widely promoted in Europe. Treatment of infected pets is key to reducing prevalence and public health impacts. Monthly prophylactic treatment is essential to control T. callipaeda infection. Abstract: This study examines the therapeutic and year-round prophylactic efficacy of different formulations used in dogs in three Spanish areas where canine thelaziosis is endemic. The study was conducted as a Good Clinical Practice, multicentre, randomised field study in privately owned outdoor dogs naturally infected with Thelazia callipaeda . The active pharmaceutical ingredients tested were: an oral formulation of milbemycin oxime 12.5 mg combined with praziquantel 125 mg (A), a subcutaneous sustained-release formulation of moxidectin 10 g (B), a moxidectin 2.5% weight/volume (w/v) spot-on formulation combined with imidacloprid 10% w/v (C), and an eye drop formulation (6 µg) of ivermectin 10 mg/ml diluted 10% in propylene glycol (D). Infected dogs were randomly allocated to treatment Groups A, B, C and D. Dogs testing negative for T. callipaeda inspection in two visits (Day 7/Day 14 and D30) were enrolled in the prophylaxis trial and reallocated to the corresponding study group (A, B, C or D). Treatment efficacy ranged from 70.4% recorded in Group A 1 week after treatment, to 100% recorded in Group C on Day 30 and in Group B on Day 60. Treatment was more efficacious in Group D (85.7% 1 week after treatment) than A, but was never 100% efficacious as in Groups B and C. Year-round prophylactic efficacy was 83.3% in Group A, 100% in Group B, 93.5% in Group C and 87.5% in Group D. In conclusion, products containing moxidectin were highly efficacious both in treating and preventing canine thelaziosis. Milbemycin also emerged as a good option. However, the off-label use of topical or subcutaneous ivermectin should be avoided due to possible adverse reactions such as pruritus, irritation or redness. In endemic areas, monthly prophylaxis to limit the spread of T. callipaeda to new areas across Europe and reduce zoonotic risks is essential.